Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
What sector does Viridian Therapeutics Inc (VRDN) operate in?
Viridian Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Viridian Therapeutics Inc (VRDN) current stock price?
As of the latest data, Viridian Therapeutics Inc stock price is $23.34, with a previous close of $22.37. Viridian Therapeutics Inc gained $0.97 in the last trading session, representing a 4.34% increase.
What is Viridian Therapeutics Inc (VRDN) current market capitalization?
Viridian Therapeutics Inc market cap is approximately 2.64 billion.
What is Viridian Therapeutics Inc (VRDN) Earnings Per Share (EPS)?
The trailing EPS is -$3.39, and the forward EPS is -$2.74.
What is Viridian Therapeutics Inc (VRDN) EBITDA?
Viridian Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -118.69 million.
Does Viridian Therapeutics Inc (VRDN) pay dividends?
No. Viridian Therapeutics Inc does not pay a dividend.
How did Viridian Therapeutics Inc (VRDN) perform in its most recent earnings report?
In the last report (June 30, 2026), Viridian Therapeutics Inc posted an EPS surprise of -8.25% and a revenue surprise of 1,190.91%.
When is Viridian Therapeutics Inc (VRDN) next earnings report?
Viridian Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is Viridian Therapeutics Inc (VRDN) beta (volatility) score?
Viridian Therapeutics Inc has a beta of 1.104, meaning its volatility is roughly in line with the market.
